false 0001781174 0001781174 2023-12-04 2023-12-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 4, 2023

 

 

Acrivon Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-41551   82-5125532

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

480 Arsenal Way, Suite 100

Watertown, Massachusetts

   02472
(Address of Principal Executive Offices)   (Zip Code)

(617) 207-8979

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value   ACRV   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 1.01 Entry into a Material Definitive Agreement

On December 4, 2023, Acrivon Therapeutics, Inc. (the “Company”) entered into a Third Amendment to the OncoSignature Diagnostic Agreement (the “Third Amendment”) with Akoya Biosciences, Inc. (“Akoya”) for the development of the ACR-368 OncoSignature companion diagnostic test. The Third Amendment addresses an expanded scope of work and increases total development milestone payments to Akoya to an aggregate of $17.3 million through pre-market approval by the Food and Drug Administration of the ACR-368 OncoSignature companion diagnostic across multiple indications. To date, approximately $3.8 million in development milestones have already been achieved and paid. Our cash runway guidance remains unchanged from our latest 10-Q filed November 9, 2023.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Acrivon Therapeutics, Inc.
Dated: December 8, 2023     By:  

/s/ Peter Blume-Jensen

    Name:   Peter Blume-Jensen, M.D., Ph.D.
    Title:   Chief Executive Officer and President
v3.23.3
Document and Entity Information
Dec. 04, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001781174
Document Type 8-K
Document Period End Date Dec. 04, 2023
Entity Registrant Name Acrivon Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-41551
Entity Tax Identification Number 82-5125532
Entity Address, Address Line One 480 Arsenal Way
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code (617)
Local Phone Number 207-8979
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol ACRV
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Grafico Azioni Acrivon Therapeutics (NASDAQ:ACRV)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Acrivon Therapeutics
Grafico Azioni Acrivon Therapeutics (NASDAQ:ACRV)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Acrivon Therapeutics